| scholarly article | Q13442814 |
| P2093 | author name string | Sabine Riethdorf | |
| Armin Soave | |||
| Michael Rink | |||
| P2860 | cites work | mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. | Q54377128 |
| EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. | Q54391399 | ||
| Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. | Q54443305 | ||
| Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. | Q54542903 | ||
| Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. | Q54706592 | ||
| Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. | Q54737307 | ||
| Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. | Q55043149 | ||
| A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0 | Q56538422 | ||
| Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol | Q56565999 | ||
| Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis | Q59396951 | ||
| Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project | Q59468763 | ||
| Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer | Q62660487 | ||
| Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients | Q73738343 | ||
| Detection of tumor genetic alterations of bladder carcinomas in body fluids depends on sample treatment before DNA isolation | Q73808635 | ||
| [Detection of urogenital malignant cells in the peripheral blood by nested RT-PCR using keratin 19 mRNA] | Q74285822 | ||
| The molecular detection of circulating tumor cells in bladder cancer using telomerase activity | Q77352119 | ||
| TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples | Q77353045 | ||
| Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer | Q77522095 | ||
| Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer | Q78644435 | ||
| Detection of circulating urothelial cancer cells in the blood using the CellSearch System | Q79839651 | ||
| Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer | Q81323674 | ||
| Detection of circulating tumor cells in patients with urothelial cancer | Q82210837 | ||
| The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy | Q82222981 | ||
| Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer | Q82866544 | ||
| Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR | Q83126160 | ||
| Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study | Q84659907 | ||
| EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 | Q87711943 | ||
| Bladder cancer | Q87757090 | ||
| Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream | Q88219748 | ||
| Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer | Q24608906 | ||
| Circulating DNA as biomarker in breast cancer | Q26785343 | ||
| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations | Q28066738 | ||
| Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation | Q28075719 | ||
| Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA | Q28239638 | ||
| Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases | Q28289395 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer | Q30080026 | ||
| Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors | Q30234454 | ||
| Origins, structures, and functions of circulating DNA in oncology | Q30249103 | ||
| Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study | Q33727836 | ||
| Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients | Q33867886 | ||
| Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. | Q33871874 | ||
| Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. | Q33911932 | ||
| Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. | Q34357786 | ||
| Molecular profiling of single circulating tumor cells with diagnostic intention | Q34542660 | ||
| Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 | ||
| Cancer micrometastases | Q34978121 | ||
| Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients | Q34994963 | ||
| The dynamic range of circulating tumor DNA in metastatic breast cancer | Q35000808 | ||
| Circulating tumour cells in breast cancer | Q35648376 | ||
| Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy | Q35752053 | ||
| Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer | Q35960332 | ||
| Lack of evidence for increased level of circulating urothelial cells in the peripheral blood after transurethral resection of bladder tumors. | Q35981404 | ||
| Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients | Q36141581 | ||
| Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection | Q36233833 | ||
| Biomolecular predictors of urothelial cancer behavior and treatment outcomes | Q37987066 | ||
| EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. | Q38119345 | ||
| Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent | Q38124003 | ||
| Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation | Q42390872 | ||
| Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy | Q42508303 | ||
| Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival | Q42752721 | ||
| Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells | Q43114885 | ||
| Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. | Q43200916 | ||
| Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. | Q43522827 | ||
| Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers | Q43558982 | ||
| Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. | Q44022435 | ||
| Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma | Q44045391 | ||
| Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer | Q44288628 | ||
| Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer | Q44496556 | ||
| Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. | Q44854223 | ||
| Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing | Q46302330 | ||
| Predictors of cancer-specific mortality after disease recurrence following radical cystectomy | Q46489162 | ||
| Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. | Q50546557 | ||
| The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). | Q50616289 | ||
| The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. | Q50898962 | ||
| Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. | Q51068972 | ||
| Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. | Q51744140 | ||
| HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial | Q51751068 | ||
| Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging. | Q51904626 | ||
| Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. | Q52980027 | ||
| Hematogenous Tumor Cell Spread Following Standard Transurethral Resection of Bladder Carcinoma. | Q53120509 | ||
| Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. | Q53165899 | ||
| p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. | Q53390985 | ||
| Chemotherapeutic effects on circulating tumor cells in bladder cancer. | Q53564620 | ||
| Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. | Q54180529 | ||
| Technologies for detection of circulating tumor cells: facts and vision | Q38154493 | ||
| Biology, detection, and clinical implications of circulating tumor cells | Q38268371 | ||
| The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancer | Q38273699 | ||
| Novel blood biomarkers of human urinary bladder cancer | Q38312678 | ||
| Management of advanced bladder cancer in the era of targeted therapies | Q38325780 | ||
| Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy? | Q38508249 | ||
| Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. | Q38590310 | ||
| Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. | Q38593842 | ||
| Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment | Q38627721 | ||
| Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma | Q38665052 | ||
| Cell-free circulating tumour DNA as a liquid biopsy in breast cancer | Q38699764 | ||
| Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. | Q38771051 | ||
| Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer | Q38773250 | ||
| A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy | Q38817683 | ||
| Establishment and characterization of a cell line from human circulating colon cancer cells. | Q38919576 | ||
| Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy | Q38969871 | ||
| Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer | Q39063627 | ||
| Liquid biopsies come of age: towards implementation of circulating tumour DNA. | Q39149201 | ||
| Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay | Q39162225 | ||
| Characterization of single circulating tumor cells. | Q39275082 | ||
| Circulating Tumor Cells as Cancer Biomarkers in the Clinic. | Q39339875 | ||
| Exosomes: New players in cancer (Review). | Q39382436 | ||
| Landmarks in the treatment of muscle-invasive bladder cancer | Q39413207 | ||
| Nivolumab for the treatment of bladder cancer | Q39454030 | ||
| The Role of p16INK4a Pathway in Human Epidermal Stem Cell Self-Renewal, Aging and Cancer | Q39454240 | ||
| Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study | Q39660094 | ||
| Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial | Q39712731 | ||
| Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma | Q39775377 | ||
| Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer | Q40069057 | ||
| Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer | Q40433976 | ||
| Using circulating cell-free DNA to monitor personalized cancer therapy. | Q40460053 | ||
| Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients | Q40791090 | ||
| Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study | Q40893287 | ||
| Detection of disseminated urothelial cancer cells in peripheral venous blood by a cytokeratin 20-specific nested reverse transcriptase-polymerase chain reaction | Q40931779 | ||
| Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study | Q41346526 | ||
| Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells | Q41347908 | ||
| Cell lines from circulating tumor cells | Q42135712 | ||
| Liquid biopsy: Potential and challenges. | Q42337624 | ||
| Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? | Q42343423 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1090-1110 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer | |
| P478 | volume | 6 |
| Q94546324 | Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC) |
| Q58704141 | Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring |
| Q92593651 | The clinical value of total plasma cell-free DNA in hepatitis B virus-related hepatocellular carcinoma |
| Q58116506 | The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder |
| Q64262680 | The current role of circulating biomarkers in non-muscle invasive bladder cancer |
| Q90724935 | Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements |
Search more.